Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | The impact of extramedullary multiple myeloma on outcomes with ide-cel

Saurabh Zanwar • 3 Jun 2024
ASCO 2024
Multiple Myeloma CAR-T Idecabtagene vicleucel

Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, discusses the impact of extramedullary multiple myeloma (MM) on outcomes with idecabtagene vicleucel (ide-cel). He notes that patients with extramedullary disease have significantly worse outcomes, possibly due to differing disease biology. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saurabh Zanwar

3:00
Treatment patterns in patients with AL amyloidosis after failure of frontline Dara-VCd
Saurabh Zanwar • 28 May 2024
0:45
Unmet needs that remain for patients with AL amyloidosis who fail frontline treatment
Saurabh Zanwar • 28 May 2024
1:03
Insights into the importance of a multidisciplinary approach when treating amyloidosis
Saurabh Zanwar • 28 May 2024
0:59
An overview of the most promising upcoming treatments for amyloidosis
Saurabh Zanwar • 28 May 2024

Related Videos

1:27
The real world utilization of MRD in myeloma across Europe
Bruno Paiva • 16 Jun 2024
2:41
Real-world dose de-escalation of teclistamab in patients with R/R myeloma
Saad Usmani • 17 Jun 2024
0:58
Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials
Meletios Dimopoulos • 13 Jun 2024
0:43
The use of oral ixazomib maintenance following autoSCT in patients with NDMM
Meletios Dimopoulos • 13 Jun 2024
The content of VJHemOnc is intended for healthcare professionals